Open access
Open access
Powered by Google Translator Translator

Oncology – Head and Neck

RCT | Upfront radiosurgery reduces tumor volume vs. a wait-and-scan approach in small- to medium-sized vestibular schwannoma

7 Aug, 2023 | 14:40h | UTC

Upfront Radiosurgery vs a Wait-and-Scan Approach for Small- or Medium-Sized Vestibular Schwannoma: The V-REX Randomized Clinical Trial – JAMA (free for a limited period)

See also: Visual Abstract

 

Commentary on Twitter

 


Review | The evolving landscape of salivary gland tumors

27 Jul, 2023 | 12:58h | UTC

The evolving landscape of salivary gland tumors – CA: A Cancer Journal for Clinicians

 


RCT | Dysphagia-optimized intensity-modulated radiotherapy better preserves swallowing function in pharyngeal cancer patients

25 Jul, 2023 | 13:52h | UTC

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial – The Lancet Oncology

Commentaries:

Dysphagia-Optimized vs Standard IMRT in Newly Diagnosed Patients With Head and Neck Cancer – The ASCO Post

Radiation approach improves swallowing in head, neck cancer – MDedge

 

Commentary on Twitter

 


TTMV-HPV DNA testing | Promising diagnostic and surveillance tool for HPV-linked oropharyngeal cancer

17 Jul, 2023 | 13:25h | UTC

Performance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus–Associated Oropharyngeal Cancer – JAMA Otolaryngology–Head & Neck Surgery (free for a limited period)

Invited Commentary: Circulating Human Papillomavirus Tumor DNA—Ready for Prime Time? –  – JAMA Otolaryngology–Head & Neck Surgery (free for a limited period)

 


2023 ETA clinical practice guidelines for thyroid nodule management

12 Jul, 2023 | 13:48h | UTC

2023 European Thyroid Association clinical practice guidelines for thyroid nodule management – European Thyroid Journal

 


The 2023 Bethesda System for reporting thyroid cytopathology

12 Jul, 2023 | 13:46h | UTC

The 2023 Bethesda System for Reporting Thyroid Cytopathology – Thyroid

 


RCT | Cisplatin–gemcitabine improves 3-year progression-free survival in N2–3 nasopharyngeal carcinoma compared to cisplatin–fluorouracil

16 Jun, 2023 | 14:05h | UTC

Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-Gemcitabine for the Treatment of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma – ESMO

 

Commentary on Twitter

 


Review | Updated salivary gland immunohistochemistry

5 May, 2023 | 14:55h | UTC

Updated Salivary Gland Immunohistochemistry: A Review – Archives of Pathology & Laboratory Medicine

 


RCT | Effects of Docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation

29 Mar, 2023 | 13:05h | UTC

Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation – Journal of Clinical Oncology (link to abstract – $ for full-text)

Editorial: Good Radiosensitizer Hunting – Journal of Clinical Oncology

Commentaries:

Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC – OncLive

Docetaxel as a Radiosensitizer in Cisplatin-Ineligible Patients With Locally Advanced Head and Neck Cancer – The ASCO Post

 


RCT | Hyperfractionation vs. standard fractionation in IMRT for patients with locally advanced recurrent nasopharyngeal carcinoma

22 Mar, 2023 | 13:12h | UTC

Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Hyperfractionated vs Standard-Fractionation IMRT in Locally Advanced, Recurrent Nasopharyngeal Carcinoma – The ASCO Post

 


Feasibility and efficacy of microwave ablation in the treatment of papillary thyroid microcarcinoma: a prospective cohort study

14 Mar, 2023 | 13:30h | UTC

Microwave Ablation for Papillary Thyroid Microcarcinoma with and without US-detected Capsule Invasion: A Multicenter Prospective Cohort Study – Radiology (link to abstract – $ for full-text)

 


RCT | Medial retropharyngeal nodal region sparing radiotherapy vs. standard radiotherapy in patients with nasopharyngeal carcinoma

7 Feb, 2023 | 14:09h | UTC

Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial – The BMJ

 


Salivary gland cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

27 Jan, 2023 | 12:16h | UTC

Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up – ESMO Open

 


RCT | Nivolumab plus Ipilimumab vs. EXTREME regimen as first-line treatment for recurrent/metastatic head and neck cancer

19 Jan, 2023 | 13:41h | UTC

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651 – Journal of Clinical Oncology

Commentary: First-Line Nivolumab/Ipilimumab vs EXTREME Regimen in Recurrent or Metastatic Head and Neck Cancer – The ASCO Post

 


NICE Guideline | Thyroid cancer: assessment and management

11 Jan, 2023 | 14:34h | UTC

Thyroid cancer: assessment and management – National Institute for Health and Care Excellence

 


ASCO Guideline | Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers

9 Jan, 2023 | 14:41h | UTC

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline – Journal of Clinical Oncology

News Release: ASCO Publishes New Guideline on Immunotherapy, Biomarker Testing in Advanced Head and Neck Cancer – ASCO Daily News

 


Cohort Study | Lobectomy vs. total thyroidectomy for intermediate-risk papillary thyroid carcinoma with lymph node metastasis.

6 Dec, 2022 | 13:41h | UTC

Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis – JAMA Surgery (free for a limited period)

Invited Commentary: Is Lobectomy as Effective as Total Thyroidectomy in Treating Patients With Intermediate-Risk Papillary Thyroid Carcinoma With Lateral Lymph Node Metastasis? – JAMA Surgery (free for a limited period)

 

Commentary on Twitter

 


Case–control study | GLP-1 receptor agonists linked to increased risk of thyroid cancer.

25 Nov, 2022 | 12:42h | UTC

GLP-1 Receptor Agonists and the Risk of Thyroid Cancer – Diabetes Care (link to abstract – $ for full-text)

Commentary: GLP-1 receptor agonists associated with thyroid cancer – ACP Internist

 


RCT | Low-dose immunotherapy (nivolumab) may improve outcomes when added to chemotherapy for head and neck cancer.

7 Nov, 2022 | 12:26h | UTC

Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter

 


2022 ETA Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma.

27 Oct, 2022 | 12:33h | UTC

2022 ETA Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma – European Thyroid Journal

Commentary: New EU Guidelines: Individualize Care for Thyroid Cancer in Kids – Medscape (free registration required)

 


RCT | Adjuvant capecitabine following concurrent CTX-RT in locoregionally advanced nasopharyngeal carcinoma.

17 Oct, 2022 | 12:15h | UTC

Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial – JAMA Oncology

 


4-year follow-up of a RCT | Pembrolizumab with vs. without chemotherapy in recurrent or metastatic head and neck SCC.

14 Oct, 2022 | 14:11h | UTC

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study – Journal of Clinical Oncology

Original Study: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)

 


Guideline Summary | Recommendations for care of survivors of head and neck cancer.

7 Oct, 2022 | 14:15h | UTC

Recommendations for Care of Survivors of Head and Neck Cancer – JAMA (free for a limited period)

Original Guideline: Head and neck cancer survivorship consensus statement from the American Head and Neck Society – Laryngoscope Investigative Otolaryngology

Related:

Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline – Journal of Clinical Oncology

American Cancer Society Head and Neck Cancer Survivorship Care Guideline

 


RCT | Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer.

3 Oct, 2022 | 13:42h | UTC

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) – Journal of Clinical Oncology

Commentary: Selumetinib Does Not Improve CR Rate in Differentiated Thyroid Cancer – Cancer Therapy Adviser

 

Commentary on Twitter

 


M-A of randomized trials | Prophylactic central neck lymph node dissection in low-risk thyroid carcinoma patients does not decrease the incidence of locoregional recurrence.

21 Sep, 2022 | 13:07h | UTC

Prophylactic Central Neck Lymph Node Dissection in Low-risk Thyroid Carcinoma Patients Does Not Decrease the Incidence of Locoregional Recurrence: A Meta-analysis of Randomized Trials – Annals of Surgery (link to abstract – $ for full-text)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.